MapLight operates a biopharmaceutical company that uses proprietary optogenetics and a 3D spatial transcriptomics platform to identify a pipeline of targeted therapies for a spectrum of serious CNS disorders, enabling healthcare professionals to improve the lives of patients with CNS disorders. View on: LinkedIn.com | Sales Navigator.

New Funding Raised: $225M, Series C

Round Investors: Novo Holdings (lead), 5AM Ventures, Cowen Healthcare Investments

🚀Growth Focus: Develop multiple clinical candidates to treat neurological and psychiatric disorders, including Phase 2 studies for ML-007C-MA in 2024 in schizophrenia and Alzheimer's disease.

Press: PR Newswire, FinSMEs

HQ: Palo Alto, CA

Industry: Biotechnology Research

Employee Count: 55 (⚡15% increase in last 6 months)